TUCSON, Ariz., Feb. 15 /PRNewswire/ -- Ventana Medical Systems, Inc.
(Nasdaq: VMSI) today announced the recruitment of an Executive Vice President
and Chief Operating Officer from outside the Company and the appointment of
one of its longstanding Directors as a Vice Chairman.
In announcing the recruitment of Christopher M. Gleeson as an EVP and COO,
Mr. Schuler, Ventana's Chairman of the Board, commented, "We are extremely
fortunate to have attracted Chris Gleeson to Ventana. Chris brings 25 years
of successful diagnostics general management experience to Ventana having most
recently been a Senior Vice President of Bayer Diagnostics and the General
Manager of its Critical Care Division." Mr. Schuler added, "Chris also
understands small, high-growth companies. He founded and built the most
successful independent distributor of medical diagnostic systems in Australia
prior to its acquisition by Ciba Corning Diagnostics/Chiron Diagnostics."
Mr. Schuler went on to add that "Chris' initial responsibilities will
cover all commercial activities in the U.S. market, the Company's core
Histology Business Unit and its distributor network that covers all markets
other than the United States, Europe and Japan."
Mr. Schuler also announced that fellow Board member John Patience has been
appointed Vice Chairman of the Board. "John has been an active Board member
since providing the Company with its first institutional venture capital in
mid-1989, was instrumental in recruiting me as an investor and Board member
and currently plays a key role in shaping the Company's strategic vision in
the histology lab." Mr. Schuler added that "John's appointment as Vice
Chairman formalizes the already active role he is playing in Ventana's
development."
Safe Harbor Statement: Statements in this press release which are not
strictly historical are "forward-looking" statements that are made pursuant to
the Safe Harbor provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements involve known and unknown risks, which may
cause the company's actual results in the future to differ materially from the
expected results. The risks and uncertainties that may affect the results of
the company's business are described in the company's specific filings with
the Securities and Exchange Commission.
Ventana develops, manufactures and markets instrument/reagent systems that
automate tissue preparation and slide staining in histology laboratories
worldwide. Ventana's systems are important tools used in the diagnosis and
treatment of cancer and infectious diseases.
SOURCE Ventana Medical Systems, Inc.
 back to top
CONTACT:
Henry T. Pietraszek, President and Chief
Executive Officer of Ventana Medical Systems, Inc., 520-887-2155;
or General Inquiries, Bill Murphy, Analyst Contact, Kathy
Brunson, or Media Inquiries, Bess Gallanis, all of The Financial
Relations Board, 312-266-7800
NOTE TO EDITORS: For more information on Ventana Medical Systems,
Inc. via facsimile at no additional cost, simply dial
1-800-PRO-INFO and enter the stock symbol "VMSI".
|
